BDX
Becton, Dickinson and Company
BDX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BDX overall, supported by stronger fundamentals and stronger modeled upside.
BDX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Under pressure |
BDX's profitability and cash flow are currently healthy, but its revenue and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BDX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $216 | — |
| Cheap | 36x | $119 | -45% |
| Fair | 46x | $152 | -30% |
| Current | 52x | $216 | — |
| Expensive | 62x | $204 | -5.3% |
Historical ranges are pointers, not guarantees.
BDX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BDX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect BDX's earnings to grow and its profitability to improve, with its revenue holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BDX on the outlook, with more favorable revenue expectations.
BDX Earnings Per Share
BDX and LLY do not have enough comparable growth data to identify a winner.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
BDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5B | -9.5% |
| Q1 2026 | $4.7B | -11% |
| Q4 2025 | $5.3B | +1.6% |
| Q3 2025 | $5.9B | +8.4% |
| Q2 2025 | $5.5B | +10% |
| Q1 2025 | $5.3B | +4.5% |
| Q4 2024 | $5.2B | +9.8% |
| Q3 2024 | $5.4B | +6.9% |
BDX's revenue grew through 2023 and has held roughly level since: $5B last quarter, down 9.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -2.7 points |
| Q1 2026 | 2% | -8.4 points |
| Q4 2025 | 11% | +1.7 points |
| Q3 2025 | 12% | +0.4 points |
| Q2 2025 | 16% | +4 points |
| Q1 2025 | 10% | -4.2 points |
| Q4 2024 | 8.8% | -0.6 points |
| Q3 2024 | 11% | +4.6 points |
BDX's operating margin was 13% last quarter, down 2.7 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BDX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BDX on profitability, with a higher operating margin.
BDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $633M | -39% |
| Q1 2026 | $546M | +1460% |
| Q4 2025 | $549M | -6.6% |
| Q3 2025 | $1B | +14% |
| Q2 2025 | $1B | -6.5% |
| Q1 2025 | $35M | -91% |
| Q4 2024 | $588M | -20% |
| Q3 2024 | $882M | -14% |
BDX's free cash flow has been positive every quarter for seven years: $2.7B over the past year, up 7.1% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BDX on cash flow, with more consistent year-over-year improvement.
BDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -5.5M shares |
| 1 year | -4.2% | -12.1M shares |
| 3 years | -4.4% | -12.8M shares |
| 5 years | -8% | -24M shares |
| Available history | -2.3% | -6.5M shares |
BDX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $2B |
| Q4 2025 | $250M |
| Q3 2025 | $250M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $750M |
| Q3 2024 | — |
BDX spent $2.5B buying back its own shares over the past year, about three times what it spent the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BDX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 3.7x | Elevated |
| Q1 2026 | 3.5x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.7x | Elevated |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 3.8x | Elevated |
| Q3 2024 | 3.9x | Elevated |
BDX's net debt is about 3.7 years of its operating earnings (EBITDA), about the same as a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over BDX on leverage, with a lower net debt burden relative to earnings.
BDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.7 | Overbought |
| Stochastic | 95.0 | Overbought |
BDX's weekly RSI is 74 (overbought) and its Stochastic is 95 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BDX PE vs Healthcare Sector
| Metric | BDX | Sector median | Relative |
|---|---|---|---|
| PE | 52x | 26x | 102% above |
| PE % | 74 | 29 | 45 pts above |
BDX is trading at 52x earnings, a 102% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over BDX on valuation relative to its sector.
BDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $195.1 | 11% above |
| 20 week MA | $181.8 | 19% above |
| 50 week MA | $166.8 | 29% above |
| 100 week MA | $161.5 | 34% above |
| 200 week MA | $176.9 | 22% above |
BDX has climbed back above all five of its weekly moving averages, and it's now 22% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
BDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $209.3 | $190.2 | -9.1% |
| 2021 | $190.2 | $190.9 | +0.4% |
| 2022 | $190.9 | $200.1 | +4.8% |
| 2023 | $200.1 | $191.7 | -4.2% |
| 2024 | $191.7 | $179.6 | -6.3% |
| 2025 | $179.6 | $154.4 | -14% |
| 2026 YTD | $154.4 | $215.7 | +40% |
BDX has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.